Autophagy inhib 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


«12...113114115116117118119120121122123124125»
  • ||||||||||  Journal:  Harnessing autophagic network is essential for trophoblast stem cell differentiation. (Pubmed Central) -  Mar 10, 2020   
    In addition, inhibition of autophagy was associated with a decrease in nuclear size of trophoblast giant cells. Taken together, these data highlight that autophagy is a necessary prelude in commitment of trophoblast differentiation from the multipotent trophoblast stem cells probably by regulating protein turnover at the onset of differentiation.
  • ||||||||||  sirolimus / Generic mfg.
    [VIRTUAL] AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1127;    
    Defective autophagy in BM ECs may be involved in the pathogenesis of PGF post-allotransplant. Although further validation is required, our data suggest that improving autophagy in BM ECs may be a potential therapeutic approach in PGF patients after allo-HSCT.
  • ||||||||||  hydroxychloroquine / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) -  Feb 5, 2020   
    P1/2,  N=31, Recruiting, 
    In general, our findings indicate that miR-450a-5p is a latent radiosensitizer and may represent a potential novel therapeutic target for radioresistance in ESCC. Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Mar 2020 --> Mar 2022
  • ||||||||||  chloroquine phosphate / Generic mfg.
    Trial completion:  CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) -  Jan 23, 2020   
    P1,  N=13, Completed, 
    Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Mar 2020 --> Mar 2022 Recruiting --> Completed
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) -  Jan 3, 2020   
    P1,  N=143, Active, not recruiting, 
    Active, not recruiting --> Recruiting Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Dec 2021
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Inducing and Inhibiting Autophagy to Investigate Its Interactions with MIF. (Pubmed Central) -  Nov 21, 2019   
    However, the unprecedented interest in autophagy in recent times has generated a number of tools and techniques for its study. Here, we present protocols for studying the interactions between MIF and autophagy, including for the induction and inhibition of autophagy and measuring autophagosome biogenesis and maturation.
  • ||||||||||  Journal:  Circ_016719 plays a critical role in neuron cell apoptosis induced by I/R via targeting miR-29c/Map2k6. (Pubmed Central) -  Nov 10, 2019   
    Here, we present protocols for studying the interactions between MIF and autophagy, including for the induction and inhibition of autophagy and measuring autophagosome biogenesis and maturation. Our results suggest that circ_016719 directly targets miR-29c, and thereby regulates the expression and functions of Map2k6, which significantly contributes to the pro-apoptotic role of circ_016719.
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) -  May 15, 2019   
    P1,  N=143, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Apr 2019 --> Feb 2021 | Trial primary completion date: Apr 2019 --> Feb 2020
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Enrollment change, Combination therapy:  FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) -  Aug 22, 2018   
    P1/2,  N=50, Completed, 
    Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | N=35 --> 50
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) -  Aug 14, 2018   
    P1,  N=72, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=40 --> 119 Recruiting --> Active, not recruiting | N=48 --> 72 | Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Jul 2018 --> Jul 2019
  • ||||||||||  chloroquine phosphate / Generic mfg.
    Trial completion date, Trial primary completion date:  The Addition of Chloroquine to Chemoradiation for Glioblastoma, (clinicaltrials.gov) -  Mar 21, 2018   
    P2,  N=156, Not yet recruiting, 
    Recruiting --> Active, not recruiting | N=48 --> 72 | Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2020 --> Jan 2022
  • ||||||||||  chloroquine phosphate / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) -  Mar 21, 2018   
    P1,  N=13, Recruiting, 
    Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2020 --> Jan 2022 Active, not recruiting --> Recruiting | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Jul 2018 --> May 2019
  • ||||||||||  Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date:  Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia (clinicaltrials.gov) -  Feb 23, 2018   
    P1,  N=1, Terminated, 
    Active, not recruiting --> Recruiting | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Jul 2018 --> May 2019 N=36 --> 1 | Initiation date: Nov 2015 --> Aug 2016 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Sep 2016 | Trial completion date: Mar 2023 --> Oct 2017; Inability to accrue
  • ||||||||||  hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
    Trial primary completion date, Combination therapy:  A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) -  Feb 6, 2018   
    P1/2,  N=40, Recruiting, 
    N=36 --> 1 | Initiation date: Nov 2015 --> Aug 2016 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Sep 2016 | Trial completion date: Mar 2023 --> Oct 2017; Inability to accrue Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial primary completion date, Combination therapy, Metastases:  Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) -  Aug 21, 2017   
    P1,  N=48, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Jul 2017 --> Jul 2018
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) -  Jul 17, 2017   
    P1,  N=143, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Nov 2015 Recruiting --> Active, not recruiting | N=224 --> 143 | Trial primary completion date: Apr 2018 --> Apr 2019
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial primary completion date, Combination therapy, Metastases:  Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) -  Apr 27, 2017   
    P1,  N=48, Recruiting, 
    Recruiting --> Active, not recruiting | N=224 --> 143 | Trial primary completion date: Apr 2018 --> Apr 2019 Trial primary completion date: Jan 2017 --> Jul 2017
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Trial primary completion date, Combination therapy:  FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) -  Apr 7, 2017   
    P1/2,  N=35, Active, not recruiting, 
    Trial primary completion date: Jan 2017 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Nov 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Combination therapy:  FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) -  Sep 26, 2016   
    P1/2,  N=35, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2017
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial primary completion date, Combination therapy, Metastases:  Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) -  Sep 22, 2016   
    P1,  N=48, Recruiting, 
    Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Jan 2016 --> Jan 2017
  • ||||||||||  chloroquine phosphate / Generic mfg.
    Trial initiation date, Trial primary completion date:  CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) -  Jun 5, 2016   
    P1,  N=9, Not yet recruiting, 
    Trial primary completion date: Apr 2016 --> Apr 2017 Initiation date: Feb 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Jul 2018